This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Learn about the efficacy and safety of Somavert, its tumour impact and its effect on co-morbidity management through clinical and real world data

The acromegaly disease activity tool designed to help monitor your patients

Advice and support services to help you and your patients optimise your experience with Somavert about the efficacy and safety of Somavert through clinical and real world data

Learn about funding and reimbursement England, Scotland, Wales and Northern Ireland

Watch and listen to acromegaly experts talk about various topics in the disease area as well as recordings from our National Nurse Meeting and the Acromegaly co-morbidity series

Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Somavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated.

Using Somavert

Somavert has a positive dose response, and dosing should be titrated to optimise IGF-I normalisation and improve symptoms1,2

Help find their personal optimum

The daily dose of Somavert should be adjusted ±5 mg every 4–6 weeks to achieve and maintain IGF-I normalisation and optimal therapeutic response *1

Simplified proportion of patients achieving IGF-I control on each dose shown for illustrative purposes. *Maximum recommended dose of Somavert should not exceed 30 mg/daily.

Discover how patients can incorporate daily self-administration into their routine

A Somavert patient demonstrates how the pre-filled diluent syringe enables straightforward reconstitution and administration at home

The Somavert prescribing guide

Find information on funding, initiation, homecare and follow-up

Download the guide

Learn about the pharmacist's role in Homecare

Vicky Ruszala, Specialist Pharmacist in Diabetes and Endocrinology, North Bristol NHS Trust explains the main roles of the pharmacist from medicines optimisation and BlueTeq funding arrangements to homecare service provision

Discover more webinars

Explore more

Contact us

To find out more about ACRODAT, supporting your patients or to order starter kits 

Contact us

Starter kits

Help your patients feel confident with Somavert and self-administration

Learn more

References 

1. Somavert Summary of Product Characteristics. Available here
2. Trainer PJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342(16):1171-7


PP-SOM-GBR-0954. June 2021

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No